Experience

PLAIO - Digitalised Pharma Planning

• Iceland
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Vice President of Global Business Development

  • May 2022 - Present



ORF Genetics hf.

• Iceland
• Biotechnology Research
• 1 - 100 Employee

• Chief Sales Officer - North America & UK

  • Dec 2020 - Present

• International Key Account Director

  • Apr 2018 - Dec 2020

• International Key Account Manager

  • Apr 2015 - Apr 2018

  ORF Genetics is a pioneer in the manufacturing of growth factors and other recombinant proteins in plants. The company’s leading product line is BIOEFFECT. Representing the future of scientific skin car. Based on 10 years of biotechnology research in Iceland they contain EGF cellular activator, a skin protein which signals the skin to speed up its renewal process. The EGF is copied from human skin and made in barley seeds to ensure maximum efficacy and purity.Developed in collaboration with leading specialists in biochemistry and dermatology, the BIOEFFECT EGF Serum and BIOEFFECT DAYTIME bring youthful glow and radiance to even the most stressed or sensitive skin.product line ISOkine™ growth factors are produced in the company’s proprietary Orfeus™ system in barley, bypassing the use of bacterial or animal cell systems.Secondary the company is offering its unique ISOkine™ growth factors for various medical research, cell culture media and diagnostics.We promise unprecedented purity of our products. The use of the unique Orfeus™ production method in barley seed, ensures that our products are void of animal components and endotoxins that can significantly compromise stem cell cultures. Show less



RISK Medical Solutions - RetinaRisk

• Iceland
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Board Member

  • Apr 2015 - Apr 2019

• Managing Director

  • Jan 2009 - Apr 2015

  Risk Medical Solutions/RetinaRisk is an Medical Device Company that builds individualised algorithms that optimize healthcare systems. The ideaology behind the company "the individualisation of health-care resources" strives to improve efficiency quality of care for patients. Our first product focuses on diabetic retinopathy, the most common cause of blindness in the world today. We calculate individual risk levels for individual patients, which are used to determine the frequency of diabetic retinopathy screening.Diabetic patients with high risk for progression of diabetic retinopathy are screened more frequently than those with low risk. Compared with the present gold standard of annual screening our system provides the same benefits with 50% fewer screening visits.This means the cost of running diabetic screening programs can be cut in half.Please see more information on our company and products at www.risk.isThe future of health care lies in the increased value for patients in terms of quality of treatment relative to dollars expended in a given systemThe primary service our company provides for health care systems is a comprehensive health program evaluation/feasibility study (report) on a sector, number of sectors or a health care system as a whole. Show less



Lipid Pharmaceutical

• CFO

  • May 2009 - Apr 2015

  Founded in January 2008 in co-operation between Lysi hf. and the dept. of Pharmacy, University of Iceland. The purpose of the project is to develop, register and market drug products that have anti-inflammatory, anti-viral and laxative effects that are produced from Icelandic fish oil ingredients. Lipid Pharmaceuticals aims to manufacture drugs and drug related products using more environmentally friendly processes and methods than are currently in practice. The base of our manufacturing process is free fatty acids derived from fish oil and supplied by Lysi hf., the company´s main investor. Our aim is to manufacture an Icelandic green product that can compete with leading international companies. Show less